1. France Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Amplitude Surgical S.A.

Amplitude Surgical S.A.

AMPLI.PA
Amplitude Surgical S.A.undefined flagEuronext Paris
6.25
EUR
- -
- -
299.85MMarket Cap
Amplitude Surgical S.A.
AMPLI.PA
(Euronext Paris)

Recent

price

6.25

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
FRC
- -
1.48
1.58
1.82
1.51
1.72
1.99
2.14
2.15
1.85
1.73
1.82
2.09
2.21
Revenue per Share
-0.07
-0.06
-0.07
-0.09
-0.38
- -
-0.26
-0.2
-0.19
-0.3
-0.29
-0.09
0.82
0.03
Basic EPS, GAAP
-0.11
-0.29
-0.28
-0.48
-0.59
-0.34
-0.47
-0.1
-0.18
0.26
0.05
0.17
0.17
0.08
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.06
-0.05
-0.06
-0.08
-0.37
0.01
-0.25
-0.19
-0.18
-0.29
-0.28
-0.08
0.83
0.04
Book Value per Share
-1.67
-1.7
-1.83
-2.44
0.35
0.29
-0.13
-0.89
-1.04
-1.19
-1.42
-1.48
-0.66
-0.84
Tangible Book Value per Share
32
32
32
32
47
47
47
47
48
48
48
48
48
48
Basic Weighted Avg Shares
- -
47
50
58
71
81
93
100
103
88
83
88
100
106
Sales/Revenue/Turnover
- -
12.5
9.92
8.7
-3.32
-8.27
0.58
2.58
1.75
-1.66
-1.63
1.94
10.84
12.17
Operating Margin (%)
- -
4
5
6
15
21
6
16
22
15
19
16
13
11
Depreciation Expense
-2
-2
-2
-3
-18
- -
-12
-9
-9
-14
-14
-4
39
2
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5.69
Effective Tax Rate (%)
- -
-4.27
-4.28
-4.89
-24.82
0.27
-12.91
-9.41
-8.76
-16.08
-17.05
-5.02
39.17
1.44
Profit Margin (%)
16
-6
12
9
67
72
77
55
50
47
56
53
54
48
Working Capital
71
54
79
101
69
76
117
115
116
124
138
127
95
102
LT Debt
25
22
20
22
119
118
103
95
85
71
57
53
96
96
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5.81
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
8.28
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
7.32
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
43.9%
7.57%
0.01%
Free Cash Flow
-6.47%
-27.33%
-50.06%
Net Income, GAAP
-631.22%
-220.26%
-96.11%
Sales/Revenue/Turnover
6.69%
1.18%
5.81%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
100
2024
- -
- -
- -
- -
106
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.82
2024
- -
- -
- -
- -
0.03
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
LifePoint, Inc. (LFPI)
Becton, Dickinson and Company (BDX.SW)
Precision Optics Corporation, Inc. (POCI)
Austco Healthcare Limited (AHC.AX)
Sysmex Corporation (6869.T)
Remedent, Inc. (REMI)
Business
Amplitude Surgical SA (AMPLI.PA), founded in 1997 and headquartered in Valence, France, designs, develops, manufactures, and markets high-end orthopedic implants and related products for primary and revision surgery targeting pathologies of the hip, knee, and lower extremities, including foot and ankle procedures; its core offerings encompass comprehensive ranges of hip and knee prostheses, extremity implants, orthopedic instruments, and innovative services such as the AMPLIVISION computer-assisted surgery system, i.M.A.G.E. single-use made-to-measure instruments, and E.T.O.I.L.E. technology platform for less-invasive anterior approaches. The company serves hospitals and healthcare facilities through a direct sales force and exclusive agents/distributors, with France generating the majority of sales at approximately 72.5% and international operations spanning more than 35 countries via subsidiaries in regions including Australia, Brazil, and the United States. In a major development, Zydus Lifesciences Limited completed the acquisition of 100% of Amplitude Surgical's share capital in October 2025, following an initial 75.4% stake purchase from PAI Partners and management in July 2025 and subsequent tender offer for the remainder, marking a strategic shift to full ownership by the Indian healthcare group after agreements signed in March and April 2025. As of fiscal year 2024 ended June 30, Amplitude Surgical reported consolidated sales of €106.0 million and EBITDA of €27.1 million, employing around 434 people with ongoing emphasis on R&D, manufacturing investments, and global expansion.